Arcutis Biotherapeutics (ARQT) Competitors

$19.50 -0.53 (-2.65%)

Closing price 04:00 PM Eastern

Extended Trading

$19.51 +0.01 (+0.05%)

As of 04:10 PM Eastern

ARQT vs. AXSM, ELAN, RDY, ARWR, and ABVX

Should you buy Arcutis Biotherapeutics stock or one of its competitors? MarketBeat compares Arcutis Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcutis Biotherapeutics include Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), Dr. Reddy's Laboratories (RDY), Arrowhead Pharmaceuticals (ARWR), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Axsome Therapeutics (NASDAQ:AXSM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

81.5% of Axsome Therapeutics shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arcutis Biotherapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 74.51%. Axsome Therapeutics has a consensus target price of $251.26, suggesting a potential upside of 11.05%. Given Arcutis Biotherapeutics' higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Arcutis Biotherapeutics and Arcutis Biotherapeutics both had 3 articles in the media. Axsome Therapeutics' average media sentiment score of -0.35 beat Arcutis Biotherapeutics' score of -0.67 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Axsome Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a beta of 1.58, meaning that its share price is 58% more volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Arcutis Biotherapeutics has higher earnings, but lower revenue than Axsome Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	6.48	-$16.14M	-$0.03	N/A
Axsome Therapeutics	$638.50M	18.24	-$183.17M	-$3.73	N/A

Arcutis Biotherapeutics has a net margin of -0.57% compared to Axsome Therapeutics' net margin of -26.59%. Arcutis Biotherapeutics' return on equity of -1.41% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Summary

Axsome Therapeutics beats Arcutis Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Elanco Animal Health presently has a consensus price target of $28.20, suggesting a potential upside of 41.89%. Arcutis Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 74.51%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arcutis Biotherapeutics has lower revenue, but higher earnings than Elanco Animal Health. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.11	-$232M	-$0.50	N/A
Arcutis Biotherapeutics	$376.07M	6.48	-$16.14M	-$0.03	N/A

Arcutis Biotherapeutics has a net margin of -0.57% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Elanco Animal Health has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

97.5% of Elanco Animal Health shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 3 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 6 mentions for Elanco Animal Health and 3 mentions for Arcutis Biotherapeutics. Elanco Animal Health's average media sentiment score of 0.01 beat Arcutis Biotherapeutics' score of -0.67 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Elanco Animal Health beats Arcutis Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Arcutis Biotherapeutics' net margin of -0.57%. Dr. Reddy's Laboratories' return on equity of 12.16% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.16%	8.12%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Dr. Reddy's Laboratories currently has a consensus target price of $16.90, suggesting a potential upside of 25.51%. Arcutis Biotherapeutics has a consensus target price of $34.00, suggesting a potential upside of 74.51%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Dr. Reddy's Laboratories has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.14	$484.20M	$0.58	23.22
Arcutis Biotherapeutics	$376.07M	6.48	-$16.14M	-$0.03	N/A

In the previous week, Dr. Reddy's Laboratories had 4 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 3 mentions for Arcutis Biotherapeutics. Dr. Reddy's Laboratories' average media sentiment score of -0.25 beat Arcutis Biotherapeutics' score of -0.67 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market.

Summary

Dr. Reddy's Laboratories beats Arcutis Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Arcutis Biotherapeutics currently has a consensus price target of $34.00, indicating a potential upside of 74.51%. Arrowhead Pharmaceuticals has a consensus price target of $87.80, indicating a potential upside of 19.68%. Given Arcutis Biotherapeutics' higher possible upside, equities research analysts plainly believe Arcutis Biotherapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arrowhead Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.83

Arcutis Biotherapeutics has a net margin of -0.57% compared to Arrowhead Pharmaceuticals' net margin of -48.38%. Arcutis Biotherapeutics' return on equity of -1.41% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Arrowhead Pharmaceuticals	-48.38%	-55.09%	-18.13%

Arrowhead Pharmaceuticals has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	6.48	-$16.14M	-$0.03	N/A
Arrowhead Pharmaceuticals	$622.01M	16.61	-$1.63M	-$2.15	N/A

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 20 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 23 mentions for Arrowhead Pharmaceuticals and 3 mentions for Arcutis Biotherapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.51 beat Arcutis Biotherapeutics' score of -0.67 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Arrowhead Pharmaceuticals	8 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market.

Summary

Arrowhead Pharmaceuticals beats Arcutis Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Arcutis Biotherapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

In the previous week, Abivax and Abivax both had 3 articles in the media. Abivax's average media sentiment score of -0.09 beat Arcutis Biotherapeutics' score of -0.67 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcutis Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Abivax currently has a consensus target price of $137.15, indicating a potential upside of 20.28%. Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 74.51%. Given Arcutis Biotherapeutics' higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Arcutis Biotherapeutics has higher revenue and earnings than Abivax. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.37	N/A
Arcutis Biotherapeutics	$376.07M	6.48	-$16.14M	-$0.03	N/A

Abivax has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Abivax has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-146.43%	-88.69%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Summary

Arcutis Biotherapeutics beats Abivax on 8 of the 15 factors compared between the two stocks.

Get Arcutis Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARQT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARQT vs. The Competition

Export

Metric	Arcutis Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.44B	$3.26B	$6.27B	$12.13B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-650.12	18.70	20.61	25.11
Price / Sales	6.48	281.88	578.26	91.48
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	12.57	6.59	9.72	6.63
Net Income	-$16.14M	$24.30M	$3.55B	$335.73M
7 Day Performance	-5.83%	-3.36%	-1.89%	-1.80%
1 Month Performance	-20.57%	-7.67%	-3.77%	-1.69%
1 Year Performance	33.08%	52.30%	29.58%	27.59%

Arcutis Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARQT Arcutis Biotherapeutics	3.0805 of 5 stars	$19.50 -2.6%	$34.00 +74.4%	+42.0%	$2.44B	$376.07M	N/A	150	High Trading Volume
AXSM Axsome Therapeutics	2.4733 of 5 stars	$222.63 -0.2%	$251.26 +12.9%	+111.5%	$11.48B	$638.50M	N/A	380
ELAN Elanco Animal Health	3.7118 of 5 stars	$26.21 +14.0%	$27.90 +6.5%	+54.4%	$11.43B	$4.72B	N/A	9,400	Analyst Upgrade High Trading Volume
RDY Dr. Reddy's Laboratories	3.4075 of 5 stars	$13.46 +1.5%	$16.90 +25.5%	-5.7%	$11.07B	$3.81B	17.48	27,811	Earnings Report
ARWR Arrowhead Pharmaceuticals	2.7231 of 5 stars	$79.14 +5.6%	$84.20 +6.4%	+370.7%	$10.49B	$1.09B	51.73	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARQT) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. AXSM, ELAN, RDY, ARWR, and ABVX

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Summary

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Arcutis Biotherapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arcutis Biotherapeutics (ARQT) Competitors

ARQT vs. AXSM, ELAN, RDY, ARWR, and ABVX

How does Arcutis Biotherapeutics compare to Axsome Therapeutics?

Do institutionals & insiders hold more shares of ARQT or AXSM?

Do analysts prefer ARQT or AXSM?

Does the media refer more to ARQT or AXSM?

Which has more volatility and risk, ARQT or AXSM?

Which has better valuation and earnings, ARQT or AXSM?

Is ARQT or AXSM more profitable?

Summary

How does Arcutis Biotherapeutics compare to Elanco Animal Health?

Do analysts recommend ELAN or ARQT?

Which has preferable earnings and valuation, ELAN or ARQT?

Is ELAN or ARQT more profitable?

Which has more risk and volatility, ELAN or ARQT?

Do insiders & institutionals hold more shares of ELAN or ARQT?

Does the media prefer ELAN or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Dr. Reddy's Laboratories?

Do institutionals and insiders hold more shares of RDY or ARQT?

Is RDY or ARQT more profitable?

Do analysts recommend RDY or ARQT?

Which has stronger earnings & valuation, RDY or ARQT?

Does the media prefer RDY or ARQT?

Which has more volatility and risk, RDY or ARQT?

Summary

How does Arcutis Biotherapeutics compare to Arrowhead Pharmaceuticals?

Do analysts rate ARQT or ARWR?

Is ARQT or ARWR more profitable?

Which has higher valuation and earnings, ARQT or ARWR?

Do institutionals & insiders believe in ARQT or ARWR?

Does the media favor ARQT or ARWR?

Which has more volatility and risk, ARQT or ARWR?

Summary

How does Arcutis Biotherapeutics compare to Abivax?

Does the media refer more to ABVX or ARQT?

Do analysts prefer ABVX or ARQT?

Which has stronger valuation and earnings, ABVX or ARQT?

Which has more risk and volatility, ABVX or ARQT?

Do insiders & institutionals believe in ABVX or ARQT?

Is ABVX or ARQT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARQT vs. The Competition

Arcutis Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools